Zhang Xin, Tang Wei, Li Ruishan, He Rongquan, Gan Tingqing, Luo Yihuan, Chen Gang, Rong Minhua
Research Department, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Department of Breast Surgery, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Exp Ther Med. 2016 Oct;12(4):2095-2101. doi: 10.3892/etm.2016.3613. Epub 2016 Aug 23.
Although miR-132 has been studied in various human tumors, few studies have investigated the role of miR-132 in hepatocellular carcinoma (HCC). The present study aimed to evaluate the associations between miR-132 and clinicopathological parameters, including recurrence, in patients with HCC. Reverse transcription-quantitative polymerase chain reaction analysis was used to detect the expression levels of miR-132 in 95 cases of HCC and their corresponding non-cancerous liver tissues. Th e associations between miR-132 expression levels and clinicopathological characteristics, including recurrence, were investigated in patients with HCC. miR-132 expression levels were significantly reduced in HCC tissues, as compared with adjacent non-cancerous tissues (1.9245±0.7564 vs. 2.7326±1.1475; P<0.001). The area under curve (AUC) of receiver operating characteristic (ROC) used to distinguish cancerous and non-cancerous tissues was 0.711 for miR-132 expression (95% confidence interval, 0.637-0.785; P<0.001) and the optimal cut-off value was 2.25. Expression levels of miR-132 were significantly reduced in the distant metastasis (P=0.031), advanced clinical TNM stage (P=0.022), hepatitis B virus-positive (P<0.001), NM23-expressed (P=0.034), high Ki-67 labeling index (LI; P=0.005) and tumor infiltration or no capsule groups (P=0.026). Spearman correlation analysis demonstrated that miR-132 was significantly correlated with hepatitis B virus infection (=-0.351; P<0.001), NM23 (=-0.220; P=0.032), Ki-67 LI (=-0.264; P=0.010) and tumor capsule (=-0.207; P=0.044). Kaplan-Meier analysis with the log-rank test indicated an approximate difference of 8 months, although miR-132 may exhibit inferior values for the prediction of recurrence in HCC patients (50.95 vs. 58.68 months; P=0.512). Therefore, the findings of the present study indicated that miR-132 is downregulated in HCC and may serve as a tumor suppressor in its progression.
尽管miR-132已在多种人类肿瘤中得到研究，但很少有研究调查miR-132在肝细胞癌（HCC）中的作用。本研究旨在评估miR-132与HCC患者临床病理参数（包括复发）之间的关联。采用逆转录-定量聚合酶链反应分析检测95例HCC及其相应癌旁肝组织中miR-132的表达水平。研究了HCC患者中miR-132表达水平与临床病理特征（包括复发）之间的关联。与相邻癌旁组织相比，HCC组织中miR-132表达水平显著降低（1.9245±0.7564 vs. 2.7326±1.1475；P<0.001）。用于区分癌组织和癌旁组织的miR-132表达的受试者工作特征曲线（ROC）下面积（AUC）为0.711（95%置信区间，0.637-0.785；P<0.001），最佳截断值为2.25。在远处转移（P=0.031）、临床TNM晚期（P=0.022）、乙型肝炎病毒阳性（P<0.001）、NM23表达（P=0.034）、高Ki-67标记指数（LI；P=0.005）以及肿瘤浸润或无包膜组（P=0.026）中，miR-132表达水平显著降低。Spearman相关性分析表明，miR-132与乙型肝炎病毒感染（r=-0.351；P<0.001）、NM23（r=-0.220；P=0.032）、Ki-67 LI（r=-0.264；P=0.010）和肿瘤包膜（r=-0.207；P=0.044）显著相关。Kaplan-Meier分析及对数秩检验表明，尽管miR-132在预测HCC患者复发方面可能表现出较差的值（50.95 vs. 58.68个月；P=0.512），但两者之间仍存在约8个月左右的差异。因此，本研究结果表明，miR-132在HCC中表达下调，可能在其进展过程中作为一种肿瘤抑制因子发挥作用。
